Allergen extract of Lepidoglyphus destructor. Study of the sensitivity and specificity of the diagnostic preparation in prick tests

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523426-40-00

Enrollment

Registered

2026-06-01

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy to Lepidoglyphus destructor

Brief summary

Area (mm²) of wheals induced by different concentrations of the L. destructor allergen extract, as well as the areas of wheals induced by the positive control and negative control, using the prick test

Detailed description

Safety parameters: • Overall rate, seriousness, and ratio of any adverse event (AE) by administration and by subject • Assessment of administration site reactions, systemic reactions and any medication administered for the treatment of adverse reaction (AR), Allergen profiling (ALEX technique)

Interventions

DRUGSkin Prick Test Negative control

DRUGLepidoglyphus destructor extract 450 µg/mL solution for skin-prick test

DRUGSkin Prick Test Positive control

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Area (mm²) of wheals induced by different concentrations of the L. destructor allergen extract, as well as the areas of wheals induced by the positive control and negative control, using the prick test	—

Secondary

Measure	Time frame
Safety parameters: • Overall rate, seriousness, and ratio of any adverse event (AE) by administration and by subject • Assessment of administration site reactions, systemic reactions and any medication administered for the treatment of adverse reaction (AR), Allergen profiling (ALEX technique)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 2, 2026